Is Your Website FDA Labeling? Where Promotion Crosses Into Misbranding

Your Website Is Doing More Regulatory Work Than You Think

Most medical device companies treat their website as a marketing asset. Regulatory affairs teams treat it as a liability -- and for good reason. Under FDA's framework, your company website, product landing pages, digital ads, and even social media posts can constitute labeling under federal law. That distinction carries serious consequences, including misbranding violations that can trigger warning letters, import alerts, and injunctions.

This is not a theoretical risk. FDA has cited promotional website content in warning letters to device manufacturers across product categories. If your regulatory team is not reviewing your digital presence with the same rigor applied to your Instructions for Use, you have a gap worth closing now.

How FDA Defines Labeling -- and Why Your Website Qualifies

The Federal Food, Drug, and Cosmetic Act (FD&C Act) defines 'label' as written, printed, or graphic matter on the device or its container. But 'labeling' is broader -- it includes all written, printed, or graphic matter that accompanies a device. Courts and FDA have interpreted 'accompanies' expansively since the landmark Kordel v. United States decision (1948), establishing that physical accompaniment is not required. Material that supplements or explains a product, and is used in connection with its sale, qualifies as labeling even when distributed separately or digitally.

Under 21 CFR Part 801, FDA's labeling regulations for devices, labeling must bear adequate directions for use, include required warnings, and accurately represent the device's intended use. Your website content -- particularly product description pages, clinical claim statements, and 'how it works' sections -- is evaluated against these same standards.

Intended Use and the Promotional Claim Problem

Intended use is at the core of FDA's classification and clearance framework. It is established not just by what a company submits in a 510(k) or PMA, but by the totality of evidence regarding how the device is promoted and used. Under 21 CFR 801.4, intended use is determined by the objective intent of the persons legally responsible for the labeling, including the claims made in advertising.

This creates a direct feedback loop between your website and your regulatory status. Consider common scenarios:

• Cleared for one indication, promoted for another: A device cleared for general wellness monitoring that your website describes as 'ideal for managing chronic disease' has potentially crossed into an uncleared intended use.
• Performance claims without substantiation: Phrases like 'clinically proven' or 'FDA-approved accuracy' require supporting data that meets the evidentiary standard FDA expects for labeling claims.
• Patient testimonials implying therapeutic outcomes: Third-party statements on your site can constitute implied claims. FDA's guidance on internet promotion makes clear that companies are responsible for testimonial content that suggests uses beyond cleared indications.
• Off-label promotion of prescription devices: For devices restricted under 21 CFR 801.109, promotional materials -- including websites -- must be directed to practitioners, not the general public, and must comply with prescription device labeling requirements.

Misbranding: The Legal Consequence of Getting This Wrong

Under Section 502 of the FD&C Act, a device is misbranded if its labeling is false or misleading in any particular, if it fails to bear adequate directions for use, or if required information is absent or inaccurate. Because your website qualifies as labeling, content that overstates efficacy, omits material risk information, or promotes uncleared indications can render your device misbranded -- regardless of whether the device itself is properly cleared or approved.

Misbranding is a prohibited act under Section 301 of the FD&C Act. FDA enforcement tools include untitled letters, warning letters, seizure, injunction, and criminal prosecution. For startups and emerging growth companies, a warning letter at a critical fundraising or commercial launch stage can be existential.

What a Defensible Digital Presence Looks Like

Regulatory rigor applied to digital promotion does not mean stripped-down, uninspiring content. It means disciplined, claim-substantiated communication. Practically, that involves:

• Conducting a systematic claims audit of all web pages, digital ads, and social content against your cleared or approved intended use
• Establishing a promotional material review (PMR) process with regulatory and legal sign-off before any new content goes live
• Maintaining a claims matrix that links every promotional assertion to its evidentiary basis -- clinical data, cleared labeling, or peer-reviewed literature
• Training marketing teams on FDA's promotional standards, including the distinction between disease claims and wellness claims under 21 CFR 801.3
• Reviewing FDA's guidance document 'Labeling -- Regulatory Requirements for Medical Devices' and applicable CDRH guidance on internet promotion when establishing internal standards

The Bottom Line for Founders and Regulatory Leaders

FDA does not distinguish between a glossy brochure and a polished product webpage. If your content promotes the device, describes its clinical utility, or influences the purchasing or prescribing decision, it is subject to the same legal standards as any other labeling. The companies that manage this well build review workflows that treat marketing and regulatory as integrated functions -- not separate lanes.

If your organization is launching a new product, refreshing your website, or preparing for a commercial scale-up, now is the right time to pressure-test your promotional content against FDA's labeling requirements before a reviewer does it for you.

The regulatory team at ADB Consulting and CRO Inc. works with medical device companies at every stage to build promotional review processes, conduct claims audits, and align marketing strategy with FDA's labeling framework. If you are unsure whether your current digital presence creates regulatory exposure, we invite you to book a free discovery call at adbccro.com. A focused conversation now can prevent a costly enforcement action later.

Related reading: Quality & Compliance Practice covers this in more depth.